Skip to content

Objective Measurements of Lens Opacification After Intravitreal Injections

Objective Measurements of Lens Opacification After Intravitreal Injections (MOC-IVT)

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03964597
Acronym
MOC-IVT
Enrollment
0
Registered
2019-05-28
Start date
2019-09-01
Completion date
2019-09-01
Last updated
2020-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intravitreal Injections (IVT), Lens Opacification

Keywords

Cataract, objective scatter index (OSI), average lens density (ALD)

Brief summary

The main hypothesis is the opacification of the lens would be increase by the IVT. The opacification of the lens can be objectived by : * the objective scatter index (OSI) on the OQAS device * the average lens density (ALD) on the IOLMaster device. Eligible patients will be followed at least 12 months after in intravitreal injection and the opacification of their lens is regularly controlled with OSI and ALD. The objective is to study the dynamics of lens opacification in IVT-treated eyes evaluated by OSI for at least 1 year.

Interventions

DIAGNOSTIC_TESTMeasurement of lens opacification

Measurement of OSI and ALD at inclusion and during post-IVT follow-up visits to M3, M6, and M12, +/- M18, +/- M24 and +/- M30.

Sponsors

Fondation Ophtalmologique Adolphe de Rothschild
Lead SponsorNETWORK

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* An indication of an intravenous injection of a dexamethasone 700 μg (Ozurdex®) or anti-VEGF for at least one of the two eyes for macular edema or neovessels linked to DMLA, retinal venous occlusion, diabetic macular edema or posterior uveitis * Phake patient, at least of the injected eye

Exclusion criteria

\- Pseudophakia of the injected eye

Design outcomes

Primary

MeasureTime frame
Value of the OSI (Objective Scatter Index) in one year of follow-up after IVT12 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026